Lenalidomide: all 818 studies that test it

Page 8 of 9. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.

• Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
• RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) TrialTerminatedNCT01127542Phase 2
• Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia SyndromeCompletedNCT01127386Phase 1/2
• Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal CancerTerminatedNCT01126450Phase 1
• Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOPCompletedNCT01122472Phase 3
• Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic LeukemiaCompletedNCT01116193Phase 2
• Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
• A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late RelapseCompletedNCT01111903Phase 1/2
• Lenalidomide Maintenance Post-debulking in Advanced CTCLTerminatedNCT01098656Phase 3
• Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma PatientsCompletedNCT01093196Phase 3
• Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01091831Phase 3
• Combination of Lenalidomide and Dexamethasone in Treatment of Multiple MyelomaCompletedNCT01090089Phase 3
• Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5qCompletedNCT01081431Phase 2
• Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01062152Phase 1
• Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma PatientsCompletedNCT01056679Phase 1
• S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT01055301Phase 2
• Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic SyndromeStatus unknownNCT01053806Phase 2
• Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
• Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple MyelomaCompletedNCT01042704Phase 1
• A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01038388Phase 1
• Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) PatientsTerminatedNCT01036399Phase 2
• Third-line Therapy of Multiple Myeloma a Prospective Phase I /II TrialStatus unknownNCT01010243Phase 1/2
• A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)TerminatedNCT01005979Phase 1
• Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01002703Phase 1/2
• Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell LymphomaCompletedNCT00987493Phase 1/2
• Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)CompletedNCT00981708Phase 1/2
• Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic SyndromeTerminatedNCT00977132Phase 2
• Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)TerminatedNCT00972842Phase 1/2
• The Treatment of Lenalidomide in Patients With POEMS SyndromeStatus unknownNCT00971685Phase 2
• Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT00968331Phase 2
• Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.CompletedNCT00963534Phase 1/2
• RMPT for Relapsed/Refractory Multiple MyelomaCompletedNCT00961467Phase 2
• Maintenance Therapy in Acute Myeloid Leukemia (AML) PatientsCompletedNCT00957385Phase 2
• Lenalidomide and Paclitaxel in Prostate CancerTerminatedNCT00933426Phase 1
• Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) TypeStatus unknownNCT00923663Phase 2
• Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
• A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple MyelomaCompletedNCT00915408Phase 1/2
• Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal FailureStatus unknownNCT00902915Phase 2
• Lenalidomide and R-CHOP in B-cell LymphomaCompletedNCT00901615Phase 1/2
• Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple MyelomaCompletedNCT00891384Phase 3
• A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qStatus unknownNCT00885508Phase 2
• A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) AmyloidosisCompletedNCT00883623Phase 2
• The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) AbnormalityCompletedNCT00874978Phase 2
• Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)CompletedNCT00864942Phase 1
• Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT00848328Phase 2
• Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple MyelomaCompletedNCT00847639Phase 2
• Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00840931Phase 1
• Lenalidomide In Patients With Acute Myeloid LeukemiaTerminatedNCT00839059Phase 1
• A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic LeukemiaWithdrawnNCT00829647Phase 1/2
• Lenalidomide and Decitabine in High Grade Myelodysplastic SyndromesCompletedNCT00828802Phase 1
• Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT00786851Phase 2
• Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal FunctionCompletedNCT00779922Phase 2
• Dose-finding of Lenalidomide as Maintenance in Multiple MyelomaCompletedNCT00778752Phase 1/2
• Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5CompletedNCT00761449Phase 2
• Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDSCompletedNCT00744536Phase 2
• Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLLCompletedNCT00738829Phase 1/2
• Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00735930Phase 1
• RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple MyelomaCompletedNCT00729638Phase 1
• Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00729118Phase 1
• Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)TerminatedNCT00720850Phase 2
• Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell LymphomasTerminatedNCT00704691Early Phase 1
• Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in MyelomaCompletedNCT00698776Phase 1
• Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase ITerminatedNCT00671801Phase 1
• Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)Status unknownNCT00628238Phase 2
• Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-AmyloidosisCompletedNCT00621400Phase 1/2
• Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL AmyloidosisCompletedNCT00607581Phase 2
• A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With MyelodysplasiaCompletedNCT00580242Phase 1
• Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple MyelomaCompletedNCT00555100Phase 1
• Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT00551928Phase 3
• Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLTerminatedNCT00543114Phase 1
• Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.CompletedNCT00532675Phase 1
• Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT00525447Phase 1
• A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT00502112Phase 1
• A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for MyelosuppressionCompletedNCT00482261Phase 2
• Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00478959Phase 2
• Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.CompletedNCT00466895Phase 1
• A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's DiseaseCompletedNCT00446433Phase 2
• Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of MyelodysplasiaStatus unknownNCT00434239Early Phase 1
• Maintenance Therapy Using Lenalidomide in MyelomaCompletedNCT00430365Phase 3
• Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]Status unknownNCT00424229Phase 2
• A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaCompletedNCT00419250Phase 1
• Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00415116Phase 1
• Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple MyelomaCompletedNCT00415064Phase 1
• Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic MelanomaCompletedNCT00412581Phase 1
• Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00398515Phase 1
• Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple MyelomaCompletedNCT00396045Phase 1/2
• A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's LymphomaCompletedNCT00322985Phase 2
• Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00306813Phase 1/2
• Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple MyelomaCompletedNCT00305812Phase 2
• Lenalidomide and Docetaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00253344Phase 1
• A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the PancreasTerminatedNCT00179751Phase 1/2
• A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.TerminatedNCT00179738Phase 2
• Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaTerminatedNCT00179725Phase 1/2
• Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNCT00179712Phase 1/2
• Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung CancerTerminatedNCT00179699Phase 1
• A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung CancerCompletedNCT00179686Phase 2
• Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic ChemotherapyCompletedNCT00179608Phase 1
• Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic AmyloidosisCompletedNCT00166413Phase 2
• Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00165477Phase 2
• Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00153933Phase 1

← Lenalidomide overview